Skip to content

MyMD Pharmaceuticals Enrolls First Patient in Stage 2 Scientific Trial of MYMD-1 as a Treatment for Delaying Aging and also Extending Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Firm”), a professional stage pharmaceutical company devoted to prolonging healthy life-span, today revealed that the first person has actually been registered in the Business’s Phase 2 professional trial of lead prospect MYMD-1, a dental immune regulatory authority medicine, as a therapy for delaying aging and also increasing healthy and balanced life expectancy.

The primary endpoint for the Stage 2 double-blind, placebo-controlled medical test is to attain a reduction in the distributing degrees of (TNF-α), tumor necrosis factor receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the healthy proteins in the body that cause swelling and also assist trigger the procedure of aging. The second procedures of the test will be the security, tolerability, as well as pharmacokinetics in this population of people.

” In a Stage 1 scientific trial of MYMD-1, we showed the medicine’s statistically significant efficiency in decreasing degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has authorized TNF-α reduction as the key endpoint for our Phase 2 study, which we believe placements us well for a successful Stage 2 result,” said Chris Chapman, M.D., President, Director as well as Chief Medical Officer of MyMD. “The initiation of client registration in this research study advances our mission to slow the aging procedure, stop loss of muscle cells in aging, limitation frailty, as well as extend healthy life-span.”

MyMD has actually mentioned that there are no FDA-approved medications for dealing with aging disorders and prolonging healthy life expectancy humans, a market expected to be a minimum of $600 billion by 20251 according to a significant investment bank. TNF-α blockers are one of the most recommended medications by profits, an international market of roughly $40 billion per year,2 and, according to Nature Aging journal,3 a stagnation in aging that would boost life expectancy by one year deserves $38 trillion as well as by one decade is worth $367 trillion.

Along with aging, MYMD-1’s unique action in controling the body immune system and dealing with chronic swelling is being created for the therapy of autoimmune illness, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes, and inflammatory digestive tract illness.

” We intend to begin writing procedures for a Stage 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The climbing occurrence of rheumatoid arthritis and other autoimmune as well as inflammatory illness are driving demand for TNF preventions like MYMD-1, as well as our company believe our orally carried out drug with really reduced toxicity would certainly be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”

Rheumatoid joint inflammation affects about 40 million individuals around the world.4.

Regarding MYMD-1.

Originally established for autoimmune illness, MYMD-1’s primary objective is to reduce the aging process, protect against sarcopenia and frailty, as well as extend healthy and balanced life expectancy. Because it can cross the blood-brain obstacle as well as gain access to the main nervous system (CNS), MYMD-1 is likewise placed to be a feasible therapy for brain-related problems. Its system of activity and efficacy in diseases consisting of multiple sclerosis (MS) and thyroiditis have been researched with partnerships with numerous scholastic organizations. MYMD-1 is also revealing pledge in pre-clinical studies as a prospective therapy for article- COVID-19 issues and as an anti-fibrotic as well as anti-proliferation therapeutic.

MYMD-1 has actually shown performance in pre-clinical studies in managing the immune system by executing as a discerning inhibitor of growth necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike various other treatments, MYMD-1 has been received these pre-clinical researches to selectively block TNF-α when it becomes overactivated in autoimmune illness as well as cytokine storms, yet not block it from doing its normal task of being an initial -responder to any regular sort of modest infection. MYMD-1’s simplicity of oral application is an additional differentiator compared to currently available TNF-α blockers, all of which call for distribution by shot or mixture. No accepted TNF inhibitor has ever been dosed orally. Furthermore, the medicine is not immunosuppressive as well as has actually not been shown to create the major negative effects common with traditional therapies that treat swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical company dedicated to expanding healthy and balanced life expectancy, is concentrated on creating 2 unique therapeutic systems that deal with the root causes of illness as opposed to just resolving the symptoms. MYMD-1 is a medicine platform based on a professional phase small particle that controls the body immune system to control TNF-α, which drives chronic swelling, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, boost durability, and also treat autoimmune conditions and also COVID-19- connected depression. The Business’s second medicine system, Supera-CBD, is being created to treat chronic pain, addiction as well as epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and also is being developed to resolve and also surpass the swiftly expanding CBD market, that includes both FDA approved medications as well as CBD products not currently managed as medicines. To find out more, go to www.mymd.com.